Navigation Links
Celtic Therapeutics and Resolvyx Pharmaceuticals Announce an Alliance in Ophthalmology
Date:10/26/2010

Celtic Therapeutics and Resolvyx Pharmaceuticals Announce an Alliance in... -- NEW YORK and CAMBRIDGE, Massachusetts, October 26, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Medical Equipment, Medical Pharmaceuticals, Joint Ventures, Clinical Trials & Medical Discoveries Click to view news release full screen  

Celtic Therapeutics and Resolvyx Pharmaceuticals Announce an Alliance in Ophthalmology

   

Celtic Therapeutics to Progress RX-10045 for Dry Eye Syndrome Through Phase III Clinical Development

NEW YORK and CAMBRIDGE, Massachusetts, October 26, 2010 /PRNewswire/ -- Celtic Therapeutics Holdings L.P. (Celtic Therapeutics), a successor firm to Celtic Pharma, and Resolvyx Pharmaceuticals, Inc. (Resolvyx) announced today that they have entered into an option agreement relating to Resolvyx's RX-10045, a late-stage program for the treatment of dry eye syndrome and other ophthalmic conditions. In connection with the RX-10045 option agreement, Celtic Therapeutics purchased a note convertible into Resolvyx equity.

Under the terms of the option agreement, Celtic Therapeutics has an exclusive option to acquire and license rights to Resolvyx's RX-10045, in all eye indications. RX-10045 is scheduled to enter a Phase III randomized, placebo-controlled, multi-center study in 2011. As part of the agreement, Celtic Therapeutics may also license rights to and develop another Resolvyx compound in a topical formulation for ophthalmic indications. Resolvins are a recently discovered family of naturally-occurring, small molecule lipid mediators that can be targeted to treat a wide range of diseases. Resolvins are shown to be highly potent and efficacious across a broad range of pre-clinical models of asthma, atherosclerosis, rheumatoid arthritis, inflammatory bowel disease, dry eye and retinal disease, among others.

Dry eye, one of the most common problems treated by ophthalmologists, and a $1.7 billion global market today, is a chronic, multifactorial disease of the tear ducts and ocular surfaces that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surfaces. RX-10045, a resolvin administered as a topical eye drop, produced dose-dependent, significant improvement on the primary endpoints for both the signs and symptoms of dry eye, and was generally shown to be safe and well tolerated in a large placebo-controlled Phase II study.

"Celtic Therapeutics is excited to invest in Resolvyx's groundbreaking technology, which has already demonstrated impressive efficacy and safety in patients with dry eye syndrome," commented Peter B. Corr, Co-Founder and Managing General Partner of Celtic Therapeutics. "The market for dry eye products has grown substantially over the past several years, despite the fact that most patients are not satisfied with current therapeutic options. With the potential for improved efficacy, a much faster onset of action, an improved tolerability profile, and a strong patent estate, we believe RX-10045, if approved, would represent an important step forward in the treatment of this widely prevalent condition."

"We are delighted to be allied with Celtic Therapeutics in maximizing the therapeutic potential of Resolvins to treat dry eye syndrome and other eye disease," said Jamie Nichols, Chief Operating Officer at Resolvyx. "Celtic Therapeutics brings both the capital and the world class development expertise to advance RX-10045 through Phase III development in dry eye and to maximize the potential of Resolvins to treat eye disease more broadly. This will allow Resolvyx to dedicate our resources to pursue the exceptional therapeutic potential of resolvins for non-ophthalmic diseases."

"Our investment in Resolvyx and RX-10045 demonstrates Celtic Therapeutics' focus on novel classes of biologic or small molecule therapeutics that hold the promise of significant medical advances compared to currently available treatment options," commented Stephen Evans-Freke, Co-Founder and Managing General Partner of Celtic Therapeutics. "This is the fourth such transaction we have announced to date; we have previously announced our investment in Kolltan Pharmaceuticals, which is developing second-generation monoclonal antibody drugs targeting tyrosine kinase receptors for the treatment of many cancer types, and alliances with Spirogen for the development of small molecule cytotoxic anti-cancer drugs designed to circumvent drug-resistance mechanisms, and with Bellus Health for the final Phase III development of Kiacta for the treatment of AA Amyloidosis."

About Dry Eye Syndrome

Dry eye occurs when the eye does not produce tears properly, or when the tears are not of the correct consistency and evaporate rapidly. An estimated 9 million Americans suffer from moderate to severe dry eye and an additional 20 to 30 million Americans have milder cases of dry eye, with worldwide prevalence of the disease closely paralleling that of the US. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface. Dry eye can make it more difficult to perform some visual activities for an extended period of time, and it can decrease tolerance for individuals exposed to dry environments.

About Celtic Therapeutics

Founded in 2007 by Stephen Evans-Freke and Dr. Peter B. Corr, Celtic Therapeutics is a successor firm to Celtic Pharma Management L.P., pursuing the same investment model on a larger scale. As a global private equity firm, it identifies, acquires and develops therapeutic products and related diagnostics in mid- and late-stage clinical development, in order to build one of the most valued portfolios of late-stage drug development programs in the global biopharmaceutical industry. Based in the US Virgin Islands, Celtic Therapeutics maintains acquisition, origination and drug development operations in New York City and Lausanne, Switzerland. The Celtic Therapeutics team comprises extensive experience in all aspects of management, acquisition and sale expertise as well as world class clinical and commercial development experience in the pharmaceutical sector. For further information, please visit http://www.celtictherapeutics.com.

About Resolvyx Pharmaceuticals

Resolvyx Pharmaceuticals is a privately-held biopharmaceutical company dedicated to the discovery, development and commercialization of resolvins, a novel class of therapies to treat inflammatory diseases and their complications. Resolvyx's drug R&D programs are focused on characterizing and developing resolvin-based compounds. Resolvyx currently has two programs in clinical development. RX-10045 is a topical eye drop that has completed a Phase II trial in chronic dry eye. RX-10001 is formulated for oral delivery and has completed Phase I. With its experienced management team, world-class scientists and leading investors, Resolvyx is well-positioned to capitalize on its extensive portfolio of over 80 patents and applications. The company's headquarters are in Cambridge, Massachusetts. For additional information, please visit http://www.resolvyx.com.

About Resolvins

Resolvins are a recently discovered family of naturally-occurring, small molecule lipid mediators that can be targeted to treat a wide range of diseases. In particular, resolvins act to protect healthy tissue during an inflammatory response to infection, injury or other environmental challenge, and then act to resolve inflammation and promote healing after the insult has passed. Resolvins are shown to be highly potent and efficacious in pre-clinical models of asthma, atherosclerosis, rheumatoid arthritis, inflammatory bowel disease, dry eye and retinal disease, among others. Resolvins are potential drug candidates to treat a broad range of acute and chronic diseases caused by a failure to resolve the inflammatory response and restore immune homeostasis.

ENQUIRIES U.K. Media Relations Susan Quigley, tel: +44(0)207-269-7169; Susan.Quigley@fd.com U.S. Media Relations Robert Stanislaro, tel: +1(212)850-5657; Robert.stanislaro@fd.com Irma Gomez-Dib, tel: +1(212)850-5761; Irma.Gomez-Dib@fd.com
'/>"/>

SOURCE Celtic Pharmaceutical Holdings L.P.
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Celtic Pharma Announces Issuance of U.S. Patent 7,816,323 for Xerecept® in Combination with Avastin® as a Treatment for Breast and Colon Cancers
2. Celtic Pharma Announces Initiation of Phase III Trial of TDT 067 for the Treatment of Onychomycosis
3. Celtic Pharma Announces Initiation of Pediatric Dose Tolerance Trial Evaluating XERECEPT(R) in Pediatric Patients with Primary and Metastatic Brain Tumors
4. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
5. Celtic Pharma Announces Update on Status of XERECEPT(R) Program Sale Planned in 2009
6. Celtic Pharma Provides Update on XERECEPT(R) Clinical Program
7. Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences
8. Algeta and Lumiphore Announce Global Agreement for the Development of Targeted Alpha-Pharmaceutical Therapeutics
9. BioMolecular Therapeutics, a New Global Player in RNAi Therapeutics, Launches Company and Adds Key Advisors
10. Prime Therapeutics Receives 2011 TIPPS Certification
11. Argos Therapeutics to Present Overview of its Arcelis™ Dendritic Cell-based Immunotherapy, Participate in Panel Discussion at Inaugural Cancer Immunotherapy Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... NuvoAir (formerly called Pond Healthcare Innovation), ... partnership with Novartis Pharma AG to distribute NuvoAir,s spirometry technology ... leading mobile spirometry platform and Novartis, commitment to address the ... ... ...
(Date:9/6/2017)... 6, 2017  Robert G. Szewc, M.D., is recognized ... in recognition of his contributions to the Medical field.  ... Nephrologist at the practice of Kidney and Hypertension Specialists, ... and hypertension solutions. He has worked in this position ... experience, as well as expertise in kidneys, hypertension, chronic ...
(Date:9/6/2017)... NeuroRx, a clinical stage biopharma company developing the first oral ... granted Fast Track status by the US Food and Drug ... by NRX-101 (D-cycloserine + lurasidone). The company will shortly begin ... targeting patients who are admitted to Emergency Departments with ASIB ... ...
Breaking Medicine Technology:
(Date:9/22/2017)... ... September 22, 2017 , ... ... the fallacy of an obligatory tithe, and the freedom experienced when breaking free ... creation of published author, Lysa M. Harrison. , Published by Christian Faith Publishing, ...
(Date:9/22/2017)... ... ... “Fruit of the Spirit: “Love””: a delightful adventure of two friends who play ... Spirit: “Love”” is the creation of published author, Halimah Jones, who was born and ... an avid writer, her inspiration for “Fruit of the Spirit: “Love”” blossomed from her ...
(Date:9/21/2017)... ... September 21, 2017 , ... With ProSlideshow Portrait from ... easy to do. Users can select from up to two layers of subject matter ... of a mouse all within Final Cut Pro X. , With ProSlideshow ...
(Date:9/21/2017)... ... September 21, 2017 , ... Promotional Communication:, Keeping ...      , In the competitive world of drug and device marketing and promotion, ... with FDA rules. , The FDA has issued two draft guidances that are ...
(Date:9/21/2017)... ... September 21, 2017 , ... Innovatum will ... the Global GS1 Healthcare Conference 2017 in Chicago, IL on October 17-19, 2017. ... label quality and improving patient safety. , Microscan , a global ...
Breaking Medicine News(10 mins):